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1409of treated hypertensive subjects for the presence of
subclinical LV systolic dysfunction. In a hypertensive
animal model, impairment of GLS occurred in parallel
with the accumulation of ﬁbrosis induced by pressure
overload in the LV subendocardium in the early
stage of hypertensive heart failure (4). Therefore, we
speculate that consistent reduction of LV pressure
overload throughout the 24 h by antihypertensive
medications might be important in delaying the
progression of LV systolic dysfunction and that ABP
control may be a better indicator of the effective
reduction of LV pressure overload than ofﬁce BP
control. Of note, inadequate ABP control was more
frequent at night than during the day in this cohort,
further underlining how ofﬁce BP does not provide an
adequate representation of BP values in a critical
period of the day.
Evaluating BP control by use of ABP monitoring,
but not by ofﬁce BP, may identify patients with
hypertension at higher risk of early LV systolic
dysfunction. Whether achieving BP control according
to ABP criteria may help decrease the risk of devel-
oping subclinical LV systolic dysfunction, and
possibly slow its progression to clinical heart failure,
is a hypothesis that deserves further investigation.Fusako Sera, MD
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tension 2014;63:500–6.Aortic Dissection After
Previous Aortic Valve
Replacement for Bicuspid
Aortic Valve DiseaseThe effect of bicuspid aortic valve (BAV) phenotype on
the future risk of type A aortic dissection is unknown.
On the basis of previous data (1), we hypothesized that
the risk of post–aortic valve replacement (AVR) aortic
dissection might be different in BAV insufﬁciency
versus BAV stenosis.
A meta-analysis was performed in accordance with
published guidelines (2). We conducted a systematic
search on PubMed, Embase, Ovid, and Google Scholar
by using the terms “aortic dissection,” “bicuspid
aortic valve,” “aortic valve replacement,” “previous
cardiac surgery,” and “bicuspid aortopathy.” The
search was limited to original adult human studies of
type A aortic dissection occurring after previous iso-
lated AVR surgery in patients with BAV disease and
known functional phenotype (i.e., insufﬁciency vs.
stenosis). Reports on post-AVR dissection in patients
with tricuspid aortic valve disease and after combined
procedures were excluded. Papers reporting aortic
dissection within 14 days of AVR were also excluded.
The primary endpoint was the risk of post-AVR
dissection in BAV insufﬁciency versus BAV stenosis.
All analyses were conducted using Comprehensive
Meta-Analysis version 2 (Biostat, Englewood, New
Jersey). Events were compared as odds ratios by us-
ing a 95% conﬁdence interval. A random effects
model was used to derive pooled estimates. Study-
speciﬁc estimates were calculated on the assump-
tion that type A dissection develops in 0.6% of
patients after AVR (3) and that patients undergoing
surgery for BAV disease are 6 to 8 times more likely to
present with aortic stenosis than with insufﬁciency
(4). Heterogeneity was evaluated, and a sensitivity
analysis was performed. Fixed-effect meta-regression
was performed to determine the modulating effect of
arterial hypertension/aortic diameters. Publication
bias was evaluated using a funnel plot and Begg and
Mazumdar’s rank correlation test.
The keyword-based search revealed 17,068 poten-
tial publications. After removal of 3,056 duplicate
Letters J A C C V O L . 6 6 , N O . 1 2 , 2 0 1 5
S E P T E M B E R 2 2 , 2 0 1 5 : 1 4 0 8 – 1 3
1410studies, 14,012 papers were screened using the ab-
stract. Abstract screening yielded 296 relevant papers
for full-text review, which revealed 44 eligible pa-
pers. Corresponding authors of 30 publications, who
were blinded to our study endpoint, were contacted
to obtain missing data on BAV phenotype. Thirteen
studies with 20 patients were further excluded due to
no answer from authors (n ¼ 8), no access to database
(n ¼ 4), or no database entries on BAV phenotype
(n ¼ 1). A total of 31 observational studies with
79 patients undergoing aortic dissection were thus
included in the ﬁnal analysis.
Fifty-six patients (71%) underwent previous AVR
for BAV insufﬁciency, whereas 23 (29%) underwent
AVR for BAV stenosis (p < 0.01). The pooled esti-
mate of dissection rate was 2.8% in the BAVFIGURE 1 Meta-Analysis of Post-AVR Aortic Dissection in BAV Disea
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Pooled estimate (random effects model) from 31 observational studies wi
10-fold higher risk of post–aortic valve replacement (AVR) aortic dissec
stenosis. AI ¼ aortic valve insufﬁciency; AS ¼ aortic valve stenosis; CI ¼insufﬁciency versus 0.2% in the BAV stenosis cohort
(p < 0.01). Proximal aortic diameter at the time of
AVR was available in 65 patients (82%). All but 1
patient had an aortic diameter $40 mm. There was a
tendency toward larger aortic diameters in BAV
stenosis versus BAV insufﬁciency (52  5 mm vs.
46  5 mm; p ¼ 0.06). One patient (5%) in the BAV
stenosis group had an aortic diameter #45 mm
compared with 20 patients with BAV insufﬁciency
(44%; p ¼ 0.03).
BAV insufﬁciency was associated with a 10-fold
higher risk of post-AVR aortic dissection compared
with BAV stenosis (odds ratio: 10.0; 95% conﬁdence
interval: 6.2 to 16.2; p < 0.001) (Figure 1). No evidence
of between-study heterogeneity (I2 ¼ 0%; p ¼ 0.9) or
publication bias (p ¼ 0.4) could be shown. Exclusionse
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th 79 patients undergoing aortic dissection. The results demonstrate a
tion for bicuspid aortic valve (BAV) insufﬁciency compared with BAV
conﬁdence interval.
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1411of any single trial did not alter the pooled effect
result. Meta-regression coefﬁcients were not signi-
ﬁcant for hypertension (p ¼ 0.8) or aortic diameter
(p ¼ 0.8).
Most reports of post-AVR aortic dissection include
a limited number of patients and do not differentiate
between BAV phenotypes (1). One systematic review
with 14% of BAV patients found that aortic insufﬁ-
ciency and fragility/thinning of the aortic wall were
predictive of post-AVR dissection (4).
Study limitations include the restricted focus on
BAV function only (i.e., excluding other potentially
important features) and the relevant rate of missing
data (i.e., regarding BAV morphotype and aortic
diameters).
Our meta-analysis revealed a 10-fold higher risk of
aortic dissection in patients who undergo AVR for
BAV insufﬁciency compared with BAV stenosis.
Moreover, the smaller aortic diameters in patients
with BAV insufﬁciency indicate an increased risk of
dissection at smaller diameters in this BAV cohort. In
contrast, BAV stenosis–associated aortopathy seems
to follow a more benign course post-AVR. Such in-
formation may be helpful when deciding on man-
agement of the aorta in BAV patients undergoing AVR
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II287–94.Protamine and
Bleeding Avoidance
StrategiesI read with great interest Dr. Singh’s state-of-the-art
review entitled “Bleeding Avoidance Strategies
During Percutaneous Coronary Interventions” (1).
As he points out, the HEAT-PPCI (Unfractionated
Heparin Versus Bivalirudin in Primary Percutaneous
Coronary Intervention) trial (2) has renewed interest
in heparin monotherapy with pre-loading of dual
antiplatelet therapy during percutaneous coronary
interventions (PCIs). Protamine reversal of heparin
anticoagulation can also be considered as a bleeding
management and/or bleeding avoidance strategy.
Nonetheless, protamine may be underutilized be-
cause of concerns regarding possible heparin re-
bound, cardiac and peripheral thrombotic effects,
and the potential for allergic or anaphylactic re-
actions. Protamine-related adverse events occur in
w2.6% of treated patients but may be as high as 11%
with a less restrictive deﬁnition (3). Briguori et al.
(4) previously concluded that patients who received
protamine to reverse heparin-associated bleeding
complications after coronary stent implantation did
not sustain higher rates of stent thrombosis com-
pared with similar nonprotamine-treated patients.
Protamine is generally well tolerated when routinely
used at the conclusion of cardiopulmonary bypass
procedures in patients with cardiovascular clinical
characteristics similar to patients undergoing PCI.
Meta-analysis of routine utilization of protamine
for the reversal of heparin anticoagulation post-PCI
has shown favorable results in properly selected
patients (5).
Interventionalists may consider protamine reversal
of heparin anticoagulation as a reasonable strategy
for the treatment of signiﬁcant post-procedural
bleeding events. Further clinical studies are appro-
priate to deﬁne the optimal role of protamine
post-femoral access PCI, to reverse heparin anti-
coagulation, and to potentially avoid PCI-associated
bleeding events in patients who have also under-
gone appropriate pre-loading with dual antiplatelet
therapy.
